ASKA Pharmaceutical Holdings Co.,Ltd. [4886.T]
TOKYO, May 11 (Pulse News Wire) – Aska Pharmaceutical Holdings CO.,LTD. (4886.T) announced changes in its board of directors and executive officers effective June 24, 2026.
Among the appointments, James C. Feliciano will join as a new director. Additionally, three existing directors—Jun Kojima, Takao Kimura, and Isamu Yamashita—are being promoted to directors with audit committee membership. Meanwhile, Yasuhiro Chisuga, currently serving as an auditor, will step down upon the conclusion of the fifth regular shareholders' meeting scheduled for June 24, 2026.
In related personnel moves, Executive Officer Satoshi Saito will also retire following the same shareholders' meeting. The board plans to finalize these decisions during a subsequent board meeting post-shareholders' assembly adjournment. James C. Feliciano, born on September 22, 1969, brings extensive experience to his new role.
His career highlights include positions such as President of Merck Serono (now Merck Biopharma) from November 2013 to October 2024, followed by roles as CEO of 3C Advisors GK since March 2025 and President of Surzen Biotherapeutics since December 2025.
🟡 Confidence: Standard AI-translated content.